Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Brad Manuel

Physician Assistant, Medical Burlington, MA Physician Assistant

NPI 1023088697 CMS profile 10899586

41 Mall Rd, Burlington, MA 01805

Open in the dashboard

General payments

$3,127

71 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brad Manuel of Burlington, MA is reported in the CMS Open Payments database as having received $3,127 across 71 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $435 7
2024 General $320 8
2023 General $1,340 24
2022 General $730 24
2021 General $301 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brad Manuel
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Brad Manuel were reported at $435. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Brad Manuel Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $301 $156 $41–$563 $132
2022 $730 $185 $55–$649 $149
2023 $1,340 $199 $58–$717 $160
2024 $320 $206 $62–$740 $164
2025 $435 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Boston Scientific Corporation $1,061 24 payments
  2. Abbott Laboratories $608 9 payments
  3. Relievant Medsystems, Inc. $593 8 payments
  4. Biohaven Pharmaceutical Holding Company Ltd. $244 10 payments
  5. Baudax Bio Inc. $193 4 payments
  6. Medtronic, Inc. $181 6 payments
  7. SI-BONE, Inc. $57 1 payment
  8. Pfizer Inc. $48 3 payments
  9. Vertos Medical, Inc. $38 1 payment
  10. Bioventus LLC $28 1 payment
  11. Other $76 4 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,871 70 payments
  2. Travel and Lodging $256 1 payment
Products named General payments · program years 2021–2025
  1. Intracept Pain $734 10 payments
  2. WaveWriter Alpha Prime 16 $573 16 payments
  3. Intracept Pain $568 7 payments
  4. Intracept Pain $568 7 payments
  5. Intracept Pain $568 7 payments
  6. NURTEC ODT $244 10 payments
  7. ANJESO $193 4 payments
  8. EON C $164 1 payment
  9. PROCLAIM $149 1 payment
  10. Intracept Intracept Access Instruments 2 VB (Gen 3)_NMOD $140 1 payment
  11. Other $950 32 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

1,183

Median for Physician Assistant: 241

Drug cost

$72,023

Median for Physician Assistant: $4,110

Branded share of claims

3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nurtec Odt Rimegepant Sulfate Brand 19 $34,789
Savella Milnacipran Hcl Brand 17 $13,064
Pregabalin Generic 342 $10,700
Lidocaine Generic 26 $3,946
Celecoxib Generic 39 $2,759
Gabapentin Generic 273 $2,456
Tizanidine Hcl Generic 156 $1,347
Cyclobenzaprine Hcl Generic 152 $1,160
Duloxetine Hcl Generic 28 $1,112
Meloxicam Generic 65 $326

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$49,046

Medicare's payments for the services billed

Medicare patients

483

Average age 73

Services billed

1,019

316 women, 167 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 35%
Ischemic heart disease 28%
Diabetes 23%
Chronic kidney disease 23%
COPD 22%
Atrial fibrillation 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

71 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record